| 1 |
34151705 |
10.1080/10428194.2021.1941925 |
2022 |
Efficacy of lenalidomide in a patient with systemic mastocytosis associated with <i>SF3B1</i>-mutant myelodysplastic syndrome. |
SF3B1 |
| 2 |
34265801 |
10.1097/PAS.0000000000001780 |
2022 |
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation. |
SF3B1 |
| 3 |
34448437 |
10.1080/10428194.2021.1971217 |
2022 |
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. |
SF3B1 |
| 4 |
34799485 |
10.1097/PAS.0000000000001834 |
2022 |
Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. |
SF3B1 |
| 5 |
34812550 |
10.1111/cas.15213 |
2022 |
Aberrant RNA splicing and therapeutic opportunities in cancers. |
SF3B1 |
| 6 |
34840089 |
10.1016/j.clml.2021.10.015 |
2022 |
Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations. |
SF3B1 |
| 7 |
34933652 |
10.1080/10428194.2021.2018579 |
2022 |
Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile. |
SF3B1 |
| 8 |
34998786 |
10.1016/j.clml.2021.12.008 |
2022 |
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. |
SF3B1 |
| 9 |
35014928 |
10.1080/10428194.2021.2020779 |
2022 |
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. |
SF3B1 |
| 10 |
35061527 |
10.1126/sciadv.abj8357 |
2022 |
SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia. |
SF3B1 |
| 11 |
35101379 |
10.1016/j.clml.2022.01.002 |
2022 |
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). |
SF3B1 |
| 12 |
35787095 |
10.1080/10428194.2022.2095629 |
2022 |
Impact of SF3B1 mutation in myelofibrosis. |
SF3B1 |
| 13 |
36040792 |
10.7554/eLife.78136 |
2022 |
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. |
SF3B1 |
| 14 |
32013644 |
10.1080/10428194.2020.1719089 |
2021 |
Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. |
SF3B1 |
| 15 |
32037286 |
10.1016/j.clml.2020.01.005 |
2021 |
SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia. |
SF3B1 |
| 16 |
32139296 |
10.1016/j.clml.2019.11.007 |
2021 |
Defining Acute Myeloid Leukemia Ontogeny in Older Patients. |
SF3B1 |
| 17 |
32179032 |
10.1016/j.clml.2019.12.023 |
2021 |
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. |
SF3B1 |
| 18 |
32397113 |
10.3390/ijms21093323 |
2021 |
Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes. |
SF3B1 |
| 19 |
32848129 |
10.1038/s41408-020-00351-w |
2021 |
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. |
SF3B1 |
| 20 |
33140678 |
10.1080/10428194.2020.1839647 |
2021 |
Analysis of distinct <i>SF3B1</i> hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. |
SF3B1 |
| 21 |
33585229 |
10.3389/fonc.2020.609409 |
2021 |
The Effect of <i>SF3B1</i> Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. |
SF3B1 |
| 22 |
34506616 |
10.1371/journal.pone.0257353 |
2021 |
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). |
SF3B1 |
| 23 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
SF3B1 |
| 24 |
30409066 |
10.1080/10428194.2018.1520990 |
2020 |
The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts. |
SF3B1 |
| 25 |
31680297 |
10.1002/ajh.25673 |
2020 |
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. |
SF3B1 |
| 26 |
32143579 |
10.1186/s12885-020-6681-2 |
2020 |
An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report. |
SF3B1 |
| 27 |
28836866 |
10.1080/10428194.2017.1366998 |
2019 |
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia. |
SF3B1 |
| 28 |
29367434 |
10.1074/mcp.RA117.000539 |
2019 |
Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation. |
SF3B1 |
| 29 |
29616853 |
10.1080/10428194.2018.1443452 |
2019 |
Clonal shifts in MDS - from SF3B1 to EZH2. |
SF3B1 |
| 30 |
29653964 |
10.1182/blood-2017-09-806679 |
2019 |
TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma. |
SF3B1 |
| 31 |
29937400 |
10.1016/j.clml.2018.05.016 |
2019 |
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. |
SF3B1 |
| 32 |
30038380 |
10.1038/s41375-018-0215-9 |
2019 |
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. |
SF3B1 |
| 33 |
30209976 |
10.1080/15384101.2018.1522912 |
2019 |
PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. |
SF3B1 |
| 34 |
30282833 |
10.1172/jci.insight.121438 |
2019 |
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. |
SF3B1 |
| 35 |
30508305 |
10.1002/cncr.31831 |
2019 |
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. |
SF3B1 |
| 36 |
31473630 |
10.1136/jclinpath-2019-205895 |
2019 |
Somatic <i>SF3B1</i> mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia. |
SF3B1 |
| 37 |
27121112 |
10.3109/10428194.2016.1173212 |
2018 |
Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. |
SF3B1 |
| 38 |
27771989 |
10.1080/10428194.2016.1246725 |
2018 |
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). |
SF3B1 |
| 39 |
28925785 |
10.1080/10428194.2017.1376746 |
2018 |
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. |
SF3B1 |
| 40 |
27235137 |
10.1182/blood-2016-02-700328 |
2017 |
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. |
SF3B1 |
| 41 |
27407063 |
10.1002/ijc.30263 |
2017 |
Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. |
SF3B1 |
| 42 |
27499002 |
10.1080/10428194.2016.1213829 |
2017 |
Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion. |
SF3B1 |
| 43 |
27693133 |
10.1016/j.clml.2016.08.005 |
2017 |
Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms. |
SF3B1 |
| 44 |
27810071 |
10.1016/j.cancergen.2016.08.007 |
2017 |
MYC rearranged B-cell neoplasms: Impact of genetics on classification. |
SF3B1 |
| 45 |
27840426 |
10.1038/leu.2016.330 |
2017 |
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. |
SF3B1 |
| 46 |
27936980 |
10.1080/17474086.2017.1270203 |
2017 |
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. |
SF3B1 |
| 47 |
28600336 |
10.1182/blood-2017-02-734541 |
2017 |
Diagnosis and classification of hematologic malignancies on the basis of genetics. |
SF3B1 |
| 48 |
28892161 |
10.1002/path.4982 |
2017 |
A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors. |
SF3B1 |
| 49 |
25330446 |
10.3109/10428194.2014.976821 |
2016 |
Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia. |
SF3B1 |
| 50 |
25487075 |
10.3109/10428194.2014.995648 |
2016 |
Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology. |
SF3B1 |
| 51 |
25645650 |
10.1111/ejh.12515 |
2016 |
The molecular pathogenesis of the myelodysplastic syndromes. |
SF3B1 |
| 52 |
25860243 |
10.3109/10428194.2015.1028051 |
2016 |
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. |
SF3B1 |
| 53 |
25862704 |
10.3324/haematol.2014.122069 |
2016 |
Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. |
SF3B1 |
| 54 |
26426381 |
10.1097/PAS.0000000000000523 |
2016 |
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. |
SF3B1 |
| 55 |
26446488 |
10.1038/ncomms9325 |
2016 |
LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair. |
SF3B1 |
| 56 |
26731899 |
|
2016 |
[Alternative Splicing Detection as a Biomarker for Cancer Diagnosis: A Novel Progressive Mechanism of Acute Lymphoblastic Leukemia with Alternative Splicing as a Biomarker Candidate]. |
SF3B1 |
| 57 |
24047479 |
10.3109/10428194.2013.845882 |
2015 |
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. |
SF3B1 |
| 58 |
24548608 |
10.1016/j.clml.2013.12.016 |
2015 |
Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice. |
SF3B1 |
| 59 |
24597984 |
10.3109/10428194.2014.898760 |
2015 |
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. |
SF3B1 |
| 60 |
25139387 |
10.1038/srep06098 |
2015 |
Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells. |
SF3B1 |
| 61 |
25220401 |
10.1111/cas.12532 |
2015 |
Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. |
SF3B1 |
| 62 |
25326804 |
10.1038/nm.3733 |
2015 |
Age-related mutations associated with clonal hematopoietic expansion and malignancies. |
SF3B1 |
| 63 |
25371178 |
10.1038/leu.2014.318 |
2015 |
The impact of SF3B1 mutations in CLL on the DNA-damage response. |
SF3B1 |
| 64 |
23167608 |
10.3109/10428194.2012.751530 |
2014 |
Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies. |
SF3B1 |
| 65 |
23270583 |
10.3109/10428194.2012.742528 |
2014 |
The significance of spliceosome mutations in chronic lymphocytic leukemia. |
SF3B1 |
| 66 |
23343182 |
10.3109/10428194.2013.769049 |
2014 |
New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works. |
SF3B1 |
| 67 |
23480493 |
10.3109/10428194.2013.783913 |
2014 |
Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? |
SF3B1 |
| 68 |
22571487 |
10.1111/j.1365-2141.2012.09155.x |
2012 |
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. |
SF3B1 |
Datasets
Models
